A detailed history of Merit Financial Group, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Merit Financial Group, LLC holds 11,525 shares of VERV stock, worth $62,004. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,525
Previous 11,832 2.59%
Holding current value
$62,004
Previous $57,000 3.51%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

SELL
$4.4 - $7.86 $1,350 - $2,413
-307 Reduced 2.59%
11,525 $55,000
Q2 2024

Aug 13, 2024

SELL
$4.76 - $12.79 $1,023 - $2,749
-215 Reduced 1.78%
11,832 $57,000
Q1 2024

May 06, 2024

BUY
$10.81 - $17.96 $237 - $395
22 Added 0.18%
12,047 $159,000
Q4 2023

Feb 06, 2024

BUY
$8.84 - $18.7 $5,383 - $11,388
609 Added 5.33%
12,025 $167,000
Q3 2023

Nov 07, 2023

BUY
$11.42 - $20.82 $130,370 - $237,681
11,416 New
11,416 $151,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $322M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Merit Financial Group, LLC Portfolio

Follow Merit Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Merit Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Merit Financial Group, LLC with notifications on news.